MX352180B - El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak. - Google Patents
El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak.Info
- Publication number
- MX352180B MX352180B MX2015013981A MX2015013981A MX352180B MX 352180 B MX352180 B MX 352180B MX 2015013981 A MX2015013981 A MX 2015013981A MX 2015013981 A MX2015013981 A MX 2015013981A MX 352180 B MX352180 B MX 352180B
- Authority
- MX
- Mexico
- Prior art keywords
- tweak
- provides methods
- methods
- related conditions
- antagonists
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 abstract 7
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 abstract 7
- 239000000556 agonist Substances 0.000 abstract 3
- 239000005557 antagonist Substances 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 108091029865 Exogenous DNA Proteins 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
Abstract
La presente invención se refiere a los métodos y agentes para el tratamiento de condiciones relacionadas a TWEAK, incluyendo condiciones cardiacas, hepáticas, renales, pulmonares, adiposas, esqueléticas, musculares, neuronales óseas, y del cartílago. La invención proporciona los métodos para identificar los agonistas o antagonistas de TWEAK para el tratamiento de condiciones relacionadas a TWEAK. Adicionalmente, la invención proporciona los animales transgénicos que expresan un ADN exógeno que codifica para un polipéptido de TWEAK, o fragmentos, análogos o muteínas del mismo, y métodos para utilizar tales animales para identificar los agonistas o antagonistas de TWEAK. La invención proporciona además los métodos para diagnosticar una enfermedad basada en la expresión de TWEAK. La invención también proporciona los métodos para afectar la diferenciación celular de las células progenitoras utilizando los polipéptidos, agonistas o antagonistas de TWEAK.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37161102P | 2002-04-09 | 2002-04-09 | |
PCT/US2003/011350 WO2003086311A2 (en) | 2002-04-09 | 2003-04-09 | Methods for treating tweak-related conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX352180B true MX352180B (es) | 2017-11-13 |
Family
ID=29250708
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015013981A MX352180B (es) | 2002-04-09 | 2003-04-09 | El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak. |
MXPA04009683A MXPA04009683A (es) | 2002-04-09 | 2003-04-09 | Metodos para el tratamiento de condiciones relacionadas a tweak. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04009683A MXPA04009683A (es) | 2002-04-09 | 2003-04-09 | Metodos para el tratamiento de condiciones relacionadas a tweak. |
Country Status (20)
Country | Link |
---|---|
US (5) | US20060240004A1 (es) |
EP (4) | EP1494713A4 (es) |
JP (4) | JP2005536455A (es) |
KR (2) | KR101174214B1 (es) |
CN (5) | CN1658901A (es) |
AU (1) | AU2003224950B2 (es) |
BR (1) | BRPI0309126A8 (es) |
CA (2) | CA2480745A1 (es) |
DK (1) | DK1997512T3 (es) |
EA (1) | EA011607B1 (es) |
ES (1) | ES2444121T3 (es) |
HK (1) | HK1127545A1 (es) |
IL (3) | IL164352A0 (es) |
MX (2) | MX352180B (es) |
NO (2) | NO334266B1 (es) |
NZ (2) | NZ548701A (es) |
PT (1) | PT1997512E (es) |
SI (1) | SI1997512T1 (es) |
WO (1) | WO2003086311A2 (es) |
ZA (1) | ZA200408073B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7129061B1 (en) * | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
HUP0105044A3 (en) | 1999-01-15 | 2004-07-28 | Biogen Inc Cambridge | Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
WO2001085193A2 (en) | 2000-05-08 | 2001-11-15 | Biogen, Inc. | Method for promoting neovascularization using a tweak agonist and an angiogenic factor |
US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
CN1658901A (zh) | 2002-04-09 | 2005-08-24 | 比奥根艾迪克Ma公司 | 用于治疗tweak相关病症的方法 |
WO2005053728A2 (de) * | 2003-12-01 | 2005-06-16 | Xantos Biomedicine Ag | Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik |
US7939490B2 (en) * | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
US20090068102A1 (en) * | 2005-02-17 | 2009-03-12 | Biogen Idec Ma Inc. | Treating stroke |
AU2011239311B2 (en) * | 2005-02-17 | 2014-05-22 | Biogen Ma Inc. | Treating Neurological Disorders |
WO2006089095A2 (en) * | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating neurological disorders |
EP1885388B1 (en) | 2005-05-10 | 2013-09-11 | Biogen Idec MA Inc. | Treating and evaluating inflammatory disorders |
EP1764109A1 (de) * | 2005-05-24 | 2007-03-21 | Xantos Biomedicine AG | Agonistische Antikörper, welche an den Tweak Rezeptor Fn14 binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie |
WO2006125632A2 (en) * | 2005-05-24 | 2006-11-30 | Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh | Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy |
NZ583636A (en) * | 2005-05-27 | 2011-12-22 | Biogen Idec Inc | Tweak binding antibodies |
WO2006130429A2 (en) * | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
WO2006138219A2 (en) * | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
EP2460827A1 (en) * | 2008-06-30 | 2012-06-06 | The Trustees Of The University Of Pennsylvania | Fusion proteins comprising Fn14 and an inhibitory protein |
WO2010019234A1 (en) * | 2008-08-12 | 2010-02-18 | Ihc Intellectual Asset Management, Llc | Analysis of genetic markers for peripartum cardiomyopathy |
JP5161718B2 (ja) * | 2008-09-25 | 2013-03-13 | 株式会社ゲノム創薬研究所 | 肝障害モデル動物、及びそれを用いた肝障害を改善又は予防する、薬剤若しくは食品素材のスクリーニング方法 |
MX2011007936A (es) * | 2009-01-30 | 2011-08-17 | Biogen Idec Inc | Metodos para regeneracion de tejido pancreatico. |
US8093006B2 (en) | 2009-04-02 | 2012-01-10 | Hoffmann-La Roche Inc. | Antibodies against human tweak and uses thereof |
WO2011065940A1 (en) * | 2009-11-24 | 2011-06-03 | Biogen Idec Ma Inc. | Method of supplementing culture media to prevent undesirable amino acid substitutions |
WO2011097500A2 (en) * | 2010-02-04 | 2011-08-11 | University Of Louisville Research Foundation, Inc. | The tweak/fn14 system regulates skeletal muscle atrophy and regeneration |
CA2812057A1 (en) | 2010-09-28 | 2012-04-05 | Kahr Medical Ltd. | Compositions and methods for treatment of hematological malignancies |
MX343114B (es) | 2010-10-05 | 2016-10-25 | F Hoffmann-La Roche Ag * | Anticuerpos contra la tweak humana y usos de los mismos. |
RU2462222C1 (ru) * | 2011-07-11 | 2012-09-27 | Наталья Николаевна Молчанова | Способ лечения больных артериальной гипертонией с метаболическими нарушениями |
SG2014010334A (en) * | 2011-08-23 | 2014-06-27 | Transbio Ltd | Fn14 binding proteins and uses thereof |
BR112014024903A2 (pt) | 2012-04-05 | 2017-07-11 | Hoffmann La Roche | anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos |
GB201317929D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
EP3903802A1 (en) * | 2014-08-21 | 2021-11-03 | Stealth Biotherapeutics Corp | Peptide d-arg-2',6'-dmt-lys-phe-nh2 for treating alport syndrome |
US10584175B2 (en) | 2014-10-23 | 2020-03-10 | La Trobe University | FN14-binding proteins and uses thereof |
KR101881531B1 (ko) * | 2016-11-25 | 2018-07-25 | 고려대학교 산학협력단 | 폴리-2-하이드록시에틸 메타아크릴레이트를 이용한 사이토카인의 발현능이 증가된 줄기세포의 제조방법 |
CN113616777A (zh) * | 2021-08-18 | 2021-11-09 | 中山大学附属第三医院(中山大学肝脏病医院) | 基于主要尿蛋白改善内质网应激的转化应用 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US5200313A (en) | 1983-08-05 | 1993-04-06 | Miles Inc. | Nucleic acid hybridization assay employing detectable anti-hybrid antibodies |
US4921698A (en) | 1984-05-25 | 1990-05-01 | Asahi Kasei Kogyo Kabushiki Kaisha | Polypeptide having gamma-interferon activity lacking amino acids coded by exon 4 |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
JP2874751B2 (ja) | 1986-04-09 | 1999-03-24 | ジェンザイム・コーポレーション | 希望する蛋白質をミルク中へ分泌する遺伝子移植動物 |
US5073492A (en) | 1987-01-09 | 1991-12-17 | The Johns Hopkins University | Synergistic composition for endothelial cell growth |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
AT396939B (de) | 1990-05-29 | 1993-12-27 | Alois Dipl Ing Dr Jungbauer | Komplexes virales antigen von hiv-1 bindendes rekombinantes protein |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
WO1995014772A1 (fr) | 1993-11-12 | 1995-06-01 | Kenichi Matsubara | Signature genique |
WO2000037638A2 (en) | 1998-12-22 | 2000-06-29 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
US20030198640A1 (en) | 1994-11-07 | 2003-10-23 | Human Genome Sciences, Inc. | Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta |
JPH10510986A (ja) | 1994-12-13 | 1998-10-27 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | メタロプロテイナーゼ−4のヒト組織インヒビター |
US6544761B2 (en) | 1994-12-13 | 2003-04-08 | Human Genome Sciences, Inc. | Human tissue inhibitor of metalloproteinase-4 |
CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
US7129061B1 (en) | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
EP0956351B1 (en) | 1996-08-07 | 2005-10-19 | Biogen Idec MA Inc. | A tumor necrosis factor related ligand |
US5858991A (en) | 1997-01-29 | 1999-01-12 | Vanderbilt University | Facilitation of wound healing with CM101/GBS toxin |
WO1998035061A2 (en) | 1997-02-12 | 1998-08-13 | Abbott Laboratories | Member of the tnf family useful for treatment and diagnosis of disease |
DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
JP2002512524A (ja) | 1997-06-03 | 2002-04-23 | 財団法人相模中央化学研究所 | 膜貫通ドメインを有するヒト蛋白質及びそれをコードするdna |
AU9376498A (en) | 1997-09-05 | 1999-03-22 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
ATE393222T1 (de) | 1997-09-18 | 2008-05-15 | Genentech Inc | Dcr3 polypeptid, ein tnfr homolog |
ATE424459T1 (de) * | 1997-10-10 | 2009-03-15 | Genentech Inc | Apo-3 ligand |
US20020072089A1 (en) | 1999-11-23 | 2002-06-13 | Holtzman Douglas A. | Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor |
US6046381A (en) * | 1998-04-30 | 2000-04-04 | The Regents Of The University Of California | Apolipoprotein E transgenic mice and assay methods |
AU4672199A (en) | 1998-05-20 | 1999-12-06 | Yale University | Modulation of angiogenesis and wound healing |
WO1999061471A2 (en) | 1998-05-29 | 1999-12-02 | Incyte Pharmaceuticals, Inc. | Human transmembrane proteins |
CA2345382A1 (en) | 1998-10-16 | 2000-04-27 | Immunex Corporation | Inhibitors of platelet activation and recruitment |
CN1202128C (zh) | 1998-12-08 | 2005-05-18 | 拜奥威神有限公司 | 修饰蛋白的免疫原性 |
HUP0105044A3 (en) * | 1999-01-15 | 2004-07-28 | Biogen Inc Cambridge | Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
US20020004041A1 (en) | 1999-02-19 | 2002-01-10 | Albert Matthew L. | Methods for abrogating a cellular immune response |
ATE364628T1 (de) | 1999-03-08 | 2007-07-15 | Genentech Inc | Verfahren und zusammensetzungen zur diagnose von tumoren |
US6521424B2 (en) | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
KR100510795B1 (en) | 1999-08-31 | 2005-08-30 | Compositions and Methods for the Treatment of Tumor | |
US6727225B2 (en) | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
CA2394015C (en) | 1999-12-20 | 2013-11-05 | Immunex Corporation | Tweak receptor |
US7495086B2 (en) | 1999-12-20 | 2009-02-24 | Immunex Corporation | TWEAK receptor |
AU2926401A (en) | 2000-01-03 | 2001-07-16 | Tr Associates, L.L.C. | Novel chimeric proteins and methods for using the same |
US7927602B2 (en) | 2002-07-23 | 2011-04-19 | University Of Louisville Research Foundation, Inc. | Fas ligand-avidin/streptavidin fusion proteins |
CA2400040A1 (en) | 2000-02-25 | 2001-08-30 | Immunex Corporation | Integrin antagonists |
WO2001085193A2 (en) * | 2000-05-08 | 2001-11-15 | Biogen, Inc. | Method for promoting neovascularization using a tweak agonist and an angiogenic factor |
US7498304B2 (en) | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
US20040047854A1 (en) | 2001-07-27 | 2004-03-11 | Black Roy A. | Human disintegrin protein |
NZ525140A (en) * | 2000-09-14 | 2005-10-28 | Biogen Idec Inc | Tweak receptor and Fn14 agonists as anti-angiogenic agents |
US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
JP4344519B2 (ja) | 2000-12-28 | 2009-10-14 | 旭化成ファーマ株式会社 | NF−κB活性化遺伝子 |
EP1379264A4 (en) | 2001-03-21 | 2009-07-08 | Human Genome Sciences Inc | HUMAN SECRETED PROTEINS |
US20040203083A1 (en) | 2001-04-13 | 2004-10-14 | Biosite, Inc. | Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases |
US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
US20040091473A1 (en) | 2001-07-27 | 2004-05-13 | Dubose Robert F. | Metalloproteinase-disintegrin polypeptides and methods of making and use thereof |
AU2002363354A1 (en) | 2001-07-27 | 2003-05-19 | Human Genome Sciences, Inc. | Heteromultimeric tnf ligand family members |
US20030148314A1 (en) | 2001-08-01 | 2003-08-07 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer |
US20040033495A1 (en) | 2001-08-03 | 2004-02-19 | Eos Biotechnology, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
US7087225B2 (en) | 2001-08-16 | 2006-08-08 | Human Genome Sciences, Inc. | Methods and compositions for treating metabolic bone diseases relating to human endokine alpha |
CN1658901A (zh) | 2002-04-09 | 2005-08-24 | 比奥根艾迪克Ma公司 | 用于治疗tweak相关病症的方法 |
WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
US20050008625A1 (en) | 2003-02-13 | 2005-01-13 | Kalobios, Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
WO2004074506A2 (en) | 2003-02-13 | 2004-09-02 | Mergen Ltd | Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers |
WO2004079014A2 (en) | 2003-03-04 | 2004-09-16 | Arcturus Bioscience, Inc. | Signatures of er status in breast cancer |
EP1648936B1 (en) | 2003-07-24 | 2007-06-06 | Amgen Inc. | Compositions and methods relating to multimeric and oligomeric soluble fragments of the tweak receptor |
EP1566636A1 (en) | 2004-02-23 | 2005-08-24 | AXARON Bioscience AG | Use of Tweak modulators and inhibitors for the treatment of neurological conditions |
CA2587018A1 (en) | 2004-11-08 | 2006-05-18 | University Of Maryland, Baltimore | Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
US7939490B2 (en) | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
US20090068102A1 (en) | 2005-02-17 | 2009-03-12 | Biogen Idec Ma Inc. | Treating stroke |
WO2006089095A2 (en) | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating neurological disorders |
CA2597485A1 (en) | 2005-03-07 | 2006-09-14 | Genentech, Inc. | Methods and compositions for modulating tweak and fn14 activity |
EP1885388B1 (en) | 2005-05-10 | 2013-09-11 | Biogen Idec MA Inc. | Treating and evaluating inflammatory disorders |
WO2006130429A2 (en) | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
NZ583636A (en) | 2005-05-27 | 2011-12-22 | Biogen Idec Inc | Tweak binding antibodies |
WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
WO2008048924A2 (en) | 2006-10-16 | 2008-04-24 | Biogen Idec Ma Inc. | Biomarkers of multiple sclerosis |
AU2009246640A1 (en) | 2008-05-15 | 2009-11-19 | Biogen Idec Ma Inc. | Anti-Fn14 antibodies and uses thereof |
WO2010085648A2 (en) | 2009-01-23 | 2010-07-29 | Linda Burkly C | Methods for reducing radiation-induced tissue damage |
MX2011007936A (es) | 2009-01-30 | 2011-08-17 | Biogen Idec Inc | Metodos para regeneracion de tejido pancreatico. |
MX343114B (es) | 2010-10-05 | 2016-10-25 | F Hoffmann-La Roche Ag * | Anticuerpos contra la tweak humana y usos de los mismos. |
-
2003
- 2003-04-09 CN CN038133172A patent/CN1658901A/zh active Pending
- 2003-04-09 EP EP03721647A patent/EP1494713A4/en not_active Withdrawn
- 2003-04-09 DK DK08104327T patent/DK1997512T3/da active
- 2003-04-09 KR KR1020107018497A patent/KR101174214B1/ko active IP Right Grant
- 2003-04-09 WO PCT/US2003/011350 patent/WO2003086311A2/en active Application Filing
- 2003-04-09 AU AU2003224950A patent/AU2003224950B2/en not_active Ceased
- 2003-04-09 NZ NZ548701A patent/NZ548701A/en not_active IP Right Cessation
- 2003-04-09 EA EA200401329A patent/EA011607B1/ru not_active IP Right Cessation
- 2003-04-09 PT PT08104327T patent/PT1997512E/pt unknown
- 2003-04-09 MX MX2015013981A patent/MX352180B/es unknown
- 2003-04-09 NZ NZ536348A patent/NZ536348A/en not_active IP Right Cessation
- 2003-04-09 BR BRPI0309126A patent/BRPI0309126A8/pt not_active Application Discontinuation
- 2003-04-09 CN CN2012102686488A patent/CN102793921A/zh active Pending
- 2003-04-09 CN CN201310506714.5A patent/CN103536916B/zh not_active Expired - Fee Related
- 2003-04-09 JP JP2003583337A patent/JP2005536455A/ja active Pending
- 2003-04-09 ES ES08104327T patent/ES2444121T3/es not_active Expired - Lifetime
- 2003-04-09 EP EP20080104327 patent/EP1997512B1/en not_active Expired - Lifetime
- 2003-04-09 CA CA002480745A patent/CA2480745A1/en not_active Abandoned
- 2003-04-09 MX MXPA04009683A patent/MXPA04009683A/es active IP Right Grant
- 2003-04-09 SI SI200332336T patent/SI1997512T1/sl unknown
- 2003-04-09 US US10/510,804 patent/US20060240004A1/en not_active Abandoned
- 2003-04-09 EP EP20100181810 patent/EP2301578A3/en not_active Withdrawn
- 2003-04-09 CN CN201610471339.9A patent/CN106421778A/zh active Pending
- 2003-04-09 CN CN200910165731A patent/CN101683520A/zh active Pending
- 2003-04-09 IL IL16435203A patent/IL164352A0/xx unknown
- 2003-04-09 CA CA2887716A patent/CA2887716C/en not_active Expired - Fee Related
- 2003-04-09 EP EP20100181803 patent/EP2301577A3/en not_active Withdrawn
- 2003-04-09 KR KR20047016169A patent/KR101000842B1/ko active IP Right Grant
-
2004
- 2004-09-28 IL IL164352A patent/IL164352A/en active IP Right Grant
- 2004-10-06 ZA ZA200408073A patent/ZA200408073B/en unknown
- 2004-11-08 NO NO20044857A patent/NO334266B1/no not_active IP Right Cessation
-
2009
- 2009-04-03 US US12/417,755 patent/US8506958B2/en not_active Expired - Fee Related
- 2009-06-02 HK HK09104939A patent/HK1127545A1/xx not_active IP Right Cessation
- 2009-09-01 JP JP2009202035A patent/JP5603040B2/ja not_active Expired - Fee Related
-
2011
- 2011-07-08 US US13/179,096 patent/US20120015024A1/en not_active Abandoned
- 2011-09-08 JP JP2011196571A patent/JP2012021014A/ja not_active Withdrawn
-
2013
- 2013-04-11 US US13/860,983 patent/US9011859B2/en not_active Expired - Fee Related
- 2013-12-06 NO NO20131617A patent/NO338778B1/no not_active IP Right Cessation
- 2013-12-25 IL IL230158A patent/IL230158B/en active IP Right Grant
-
2014
- 2014-01-31 JP JP2014016608A patent/JP5916776B2/ja not_active Expired - Fee Related
-
2015
- 2015-03-18 US US14/661,391 patent/US20150291688A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX352180B (es) | El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak. | |
Kerth | The science of meat quality | |
EP1009804A4 (en) | NUCLEIC ACID SEQUENCES ENCODING THE CAPSAICIN RECEPTOR AND POLYPEPTIDES SIMILAR TO THE CAPSAICIN RECEPTOR AND THEIR USE | |
NZ510367A (en) | Interleukin 17-like receptor protein nucleic acid sequence encoding the interleukin receptor protein and method of expressing protein in recombinant vector | |
BR9806954A (pt) | Receptores 6a e 6b do fator de necrose tumoral | |
IL149922A (en) | Tweak receptor antagonist for use in regulating the angiogenesis process, a nucleic acid encoded by the antagonist, expression and host cells that contain the expression carrier and the antagonist to produce the antagonist | |
PT939804E (pt) | Neutroquina alfa | |
ATE540973T1 (de) | Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung | |
EP2314617A3 (en) | ActRII receptor polypeptides | |
PL2157192T3 (pl) | Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin) | |
ATE490323T1 (de) | Adiponektin-rezeptor und dafür kodierendes gen | |
ATE360077T1 (de) | 22025, eine neue menschliche zyklische nukleotiden phosphodiesterase | |
ATE389416T1 (de) | Behandlung von knorpelerkrankungen | |
WO2005001061A3 (en) | Polynucleotides encoding novel adiponectin receptor variants | |
DK0769024T3 (da) | Höjaffinitetsmelatoninreceptor og anvendelser deraf | |
MXPA03005436A (es) | Polinucleotidos novedosos que codifican fosfastasas humanas. | |
WO2003027231A3 (en) | Polynucleotide encoding adapter protein, pmn29 | |
EA199800352A1 (ru) | ПОЛИПЕПТИД ХЕМОКИНА β-8 (ВАРИАНТЫ) И СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОМПОЗИЦИИ ПОЛИПЕПТИДОВ, ВЕКТОР, КЛЕТКА-ХОЗЯИН, АГОНИСТ И АНТАГОНИСТ, ВСЕ - УПОМЯНУТОГО ПОЛИПЕПТИДА, И СПОСОБ ИДЕНТИФИКАЦИИ ПОСЛЕДНЕГО, СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В Хк-β-8 (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В ПОДАВЛЕНИИ Хк-β-8, СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПРЕДРАСПОЛОЖЕННОСТИ К ЗАБОЛЕВАНИЮ, ОБУСЛОВЛЕННОМУ НЕДОСТАТОЧНОЙ ЭКСПРЕССИЕЙ ПОЛИПЕПТИДА | |
Richter et al. | High-mobility group protein HMGA2-derived fragments stimulate the proliferation of chondrocytes and adipose tissue-derived stem cells. | |
DE60036469D1 (de) | 17867, eine menschliche aminopeptidase | |
CY1114895T1 (el) | Μεθοδοι για αντιμετωπιση συνδεομενων me tweak καταστασεων | |
DE60221273D1 (de) | Verfahren zur steigerung der expression von menschlichen tnf-rezeptor | |
WO2005003299A3 (en) | Polynucleotides encoding novel guanylate binding proteins (gbp's) | |
ATE329027T1 (de) | Menschliches leucinereiche wiederholungen enthaltendes protein, vorwiegend im dünndarm exprimiert, hlrrsi1 | |
BRPI0408510A (pt) | métodos de identificar um membro da famìlia secfam1, de diagnosticar e de tratar uma doença em um paciente, de monitorar o tratamento terapêutico de doença em um paciente, de identificar um composto, e de triar quanto a um composto eficaz para tratar doença, polipeptìdeo, molécula de ácido nucleico purificada, vetor, célula hospedeira, ligando, composto, uso de um polipeptìdeo, composição farmacêutica, composição de vacima, kit, e, animal não humano transgênico ou de abatimento |